Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renato Tassi

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
World Journal of Experimental Medicine|March 2, 2016
Hepatocellular carcinoma: Where are we?Roberto Mazzanti, Umberto Arena, Renato Tassi
Clinical Genitourinary Cancer|December 3, 2014
Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?Renato Tassi, Valentina Baldazzi, Alberto Lapini, et al.
Urologic Oncology|October 2, 2010
The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center studyValentina Baldazzi, Renato Tassi, Alberto Lapini, et al.
Future Medicinal Chemistry|August 22, 2015
Emerging drugs in refractory colorectal cancerStefania Nobili, Alessandro Galletta, Marco Brugia, et al.
Cancer|September 30, 2011
Sunitinib-induced hyperparathyroidism: a possible mechanism to altered bone homeostasisValentina Baldazzi, Renato Tassi, Alberto Lapini, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 2, 2012
Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patientsBruno Neri, Agnese Vannini, Marco Brugia, et al.
Oncology Research|March 9, 2018
ERRATUMEnrico Mini, Ida Landini, Laura Lucarini, et al.
Oncology Research|April 22, 2017
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response PathwaysEnrico Mini, Ida Landini, Laura Lucarini, et al.
Oncology Research|December 7, 2019
Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution ExperienceStefania Nobili, Daniele Lavacchi, Gabriele Perrone, et al.
International Journal of Cancer|April 12, 2019
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapyEnrico Mini, Andrea Lapucci, Gabriele Perrone, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
World Journal of Experimental Medicine|March 2, 2016
Hepatocellular carcinoma: Where are we?Roberto Mazzanti, Umberto Arena, Renato Tassi
Clinical Genitourinary Cancer|December 3, 2014
Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?Renato Tassi, Valentina Baldazzi, Alberto Lapini, et al.
Urologic Oncology|October 2, 2010
The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center studyValentina Baldazzi, Renato Tassi, Alberto Lapini, et al.
Future Medicinal Chemistry|August 22, 2015
Emerging drugs in refractory colorectal cancerStefania Nobili, Alessandro Galletta, Marco Brugia, et al.
Cancer|September 30, 2011
Sunitinib-induced hyperparathyroidism: a possible mechanism to altered bone homeostasisValentina Baldazzi, Renato Tassi, Alberto Lapini, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 2, 2012
Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patientsBruno Neri, Agnese Vannini, Marco Brugia, et al.
Oncology Research|March 9, 2018
ERRATUMEnrico Mini, Ida Landini, Laura Lucarini, et al.
Oncology Research|April 22, 2017
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response PathwaysEnrico Mini, Ida Landini, Laura Lucarini, et al.
Oncology Research|December 7, 2019
Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution ExperienceStefania Nobili, Daniele Lavacchi, Gabriele Perrone, et al.
International Journal of Cancer|April 12, 2019
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapyEnrico Mini, Andrea Lapucci, Gabriele Perrone, et al.
Pageof 2